NAS:CRVS (USA) Also trade in: Germany

Corvus Pharmaceuticals Inc

$ 4.1 -0.08 (-1.91%)
Volume: 31,486 Avg Vol (1m): 83,790
Market Cap $: 120.24 Mil Enterprise Value $: 14.43 Mil
P/E (TTM): 0.00 P/B: 1.21
Earnings Power Value 0
Net Current Asset Value 3.26
Tangible Book 3.44
Projected FCF 0
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
67.07% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
CRVS: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
N/A
Interest Coverage No Debt
Interest Coverage ranked higher than
59.60% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
CRVS: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.87
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC 8.57%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -37.24
ROE ranked lower than
52.17% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
CRVS: -37.24
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -71.53, Med: -51.15, Max: -37.24
Current: -37.24
-71.53
-37.24
ROA % -34.36
ROA ranked lower than
56.46% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
CRVS: -34.36
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -56.47, Med: -45.73, Max: -30.49
Current: -34.36
-56.47
-30.49
ROC (Joel Greenblatt) % -2098.99
ROC (Joel Greenblatt) ranked lower than
68.05% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
CRVS: -2098.99
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -2098.99, Med: -1701.14, Max: -1452.03
Current: -2098.99
-2098.99
-1452.03
3-Year Total EBITDA Growth Rate -52.60
3-Year EBITDA Growth Rate ranked lower than
100.00% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
CRVS: -38.1
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -19.05, Max: -38.1
Current: -38.1
0
-38.1

» CRVS's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:CRVS

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare AMEX:XXII NAS:NK BOM:512529 TSE:4571 TSX:ZYME SZSE:000004 XKRX:046210 NAS:ABUS LSE:MPH TSE:4564 ROCO:4128 NAS:SVRA NAS:BSTC NAS:MBIO NAS:MNKD AMEX:BTX NAS:COOL ROCO:6586 NAS:TORC NAS:NLNK
Traded in other countries C17.Germany
Address 863 Mitten Road, Suite 102, Burlingame, CA, USA, 94010
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The company is engaged in development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. The company is developing products that either block immune checkpoints and/or reprogram immune cells. The group competes with universities and other research institutions.

Ratios

Current vs industry vs history
PB Ratio 1.21
PB Ratio ranked higher than
72.77% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
CRVS: 1.21
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 3.5
Current: 1.21
0
3.5
EV-to-EBIT -0.29
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
CRVS: -0.29
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -8.98, Med: 0, Max: 0.39
Current: -0.29
-8.98
0.39
EV-to-EBITDA -0.31
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
CRVS: -0.31
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -9.14, Med: 0, Max: 0.39
Current: -0.31
-9.14
0.39
Current Ratio 12.39
Current Ratio ranked higher than
84.82% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
CRVS: 12.39
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 10.11, Med: 16.24, Max: 111.05
Current: 12.39
10.11
111.05
Quick Ratio 12.39
Quick Ratio ranked higher than
85.10% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
CRVS: 12.39
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 10.11, Med: 16.24, Max: 111.05
Current: 12.39
10.11
111.05

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -12.80
3-Year Share Buyback Rate ranked lower than
100.00% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
CRVS: -12.8
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -12.8, Med: -6.4, Max: 0
Current: -12.8
-12.8
0

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 1.19
Price-to-Tangible-Book ranked higher than
78.97% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
CRVS: 1.19
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.97, Med: 2.42, Max: 3.68
Current: 1.19
0.97
3.68
Earnings Yield (Joel Greenblatt) % -345.72
Earnings Yield (Greenblatt) ranked lower than
81.13% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
CRVS: -345.72
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -134102.33, Med: 0, Max: 562125.16
Current: -345.72
-134102.33
562125.16

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N